<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885597</url>
  </required_header>
  <id_info>
    <org_study_id>Juanbi pill</org_study_id>
    <nct_id>NCT02885597</nct_id>
  </id_info>
  <brief_title>Juanbi Pill for Rheumatoid Arthritis</brief_title>
  <official_title>Juanbi Pill Combined With Methotrexate for Rheumatoid Arthritis: Multi-center Random Controlled Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cui xuejun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Yueyang Integrated Medicine Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Juanbi Pill combined with methotrexate are
      effective in the treatment of active Rheumatoid Arthritis (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid arthritis patients are suffering from painful and swelling of joints as well as
      joint destruction and functional disability with the duration of disease activity. Patients
      and physician try to find a way to alleviate the swell and tenderness of joints to avoid
      irreversible joints impairment, for evidence indicating that early aggressive treatment
      results in greater improvement than therapy initiated later in the disease course.

      As a complementary and alternative medicine (CAM), herbal medicines have the potential to
      achieve a clinical remission, or push the disease back to low disease activity. In
      traditional Chinese medicine (TCM), rheumatoid arthritis is a Bi syndrome and Juanbi decotion
      (notopterygium root, radix angelicae pubescentis, Gentiana macrophylla, Kadsura Pepper Stem,
      Mulberry Twig, Angelica sinensis, Ligusticum wallichii, frankincense, Radix Aucklandiae,
      shaved cinnamon barka and liquorice ) is a medicine specially for Bi syndrome and it has been
      used in Chinese for hundreds of years. Juanbi pill is the raw extration of Juanbi decotion
      for the sake of convenience of quality control and storage.

      Although the long term usage of Juanbi decotion, there is no high quality evidence about the
      decotion on rheumatoid arthritis. Using a well-designed clinical trial, the investigators
      will survey the effectiveness of concurrent use of this decotion in relieving disease
      activity. Therefore, the present study is to examine effectiveness and safety of Juanbi Pill,
      a compound traditional Chinese herbal medicine on rheumatoid arthritis in a randomized,
      double-blind, placebo-controlled trial. Results of this study will provide evidence regarding
      the value of the Juanbi pill as an intervention to lower the disease activity and protect the
      affected joints from deformity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of ACR (American College Of Rheumatology) 50</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of The Disease Activity Score (DAS) 28</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of the van der Heijde modified Sharp score</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of The Disease Activity Score (DAS) 28</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of The Disease Activity Score (DAS) 28</measure>
    <time_frame>from baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of The Disease Activity Score (DAS) 28</measure>
    <time_frame>from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of The Disease Activity Score (DAS) 28</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ACR(American College Of Rheumatology)50</measure>
    <time_frame>at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ACR(American College Of Rheumatology)50</measure>
    <time_frame>at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ACR(American College Of Rheumatology)50</measure>
    <time_frame>at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ACR(American College Of Rheumatology)50</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ACR(American College Of Rheumatology)50</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>form baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>form baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>form baseline to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>form baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>form baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>form baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of AIS Sleep Scale</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of AIS Sleep Scale</measure>
    <time_frame>from baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of AIS Sleep Scale</measure>
    <time_frame>from baseline to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of AIS Sleep Scale</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of AIS Sleep Scale</measure>
    <time_frame>from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of AIS Sleep Scale</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Juanbi Pill</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Juanbi group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants should administrate both Juanbi pill and Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants should administrate both Juanbi pill placebo and Methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Juanbi pill</intervention_name>
    <description>4g, twice a day, 3month, oral</description>
    <arm_group_label>Juanbi group</arm_group_label>
    <other_name>Experimental: Juanbi group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Juanbi pill placebo</intervention_name>
    <description>4g, twice a day, 3month, oral</description>
    <arm_group_label>placebo group</arm_group_label>
    <other_name>Placebo Comparator: placebo group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>5mg, once a week, 3 month, oral</description>
    <arm_group_label>Juanbi group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
    <other_name>Experimental: Juanbi group</other_name>
    <other_name>Placebo Comparator: placebo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with rheumatoid arthritis (score more then 5 of ACR (American College Of
             Rheumatology) /EULAR (European League Against Rheumatism), 2009 )

          -  moderate-to-severe disease activity (Disease Activity Score for 28-joint counts
             (DAS28) of more than 3.2

          -  an onset of symptoms within 12 months before enrollment, no prior exposure to more
             than 10mg oral glucocorticoids or biologic agents

          -  paid employment or unpaid but measurable work (e.g., caring for a family and home)

        Exclusion Criteria:

          -  combined with other disease such as adjuvant arthritis, lupus arthritis,
             osteoarthritis and et al.

          -  abnormal liver and my kidney function

          -  pregnancy or have a plan of pregnancy,breast feeding women

          -  severe chronic or acute disease interfering with therapy attendance

          -  alcohol or substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongjun Wang, Doctor</last_name>
    <phone>86-189177763018</phone>
    <email>yjwang8888@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qianqian Liang, Doctor</last_name>
    <phone>86-021-64875390</phone>
  </overall_contact_backup>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Cui xuejun</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Juanbi Pill</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Active</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

